Matthew Pando, PhD

Clinical Safety and Efficacy of RL-007 from a Phase2a Study of Cognition in Schizophrenia Patients

Approximately 80% of schizophrenia patients are impacted by significant cognitive impairments. RL-007, an oral pro-cognitive neuromodulator, has been evaluated in pre-clinical and clinica...

Matthew Pando , PhD;

10/26/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Matthew Pando, PhD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products